Latest California Healthline Stories
A little-noticed provision in President Donald Trump’s executive order on drug prices may offer a clue to why Big Pharma hasn’t opposed a bill that could bleed their balance sheets of millions of patients.
Report by CDC researchers finds a steady fall in opioid use in recent years, but the rates are still three times higher than in 1999.
Gabapentin, prescribed for epilepsy and nerve damage, is touted by federal health officials as an alternative to opioids for patients. But some are now abusing the drug.
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
Expertos en políticas de salud que han analizado el texto del proyecto de salud del Senado, aseguran que la legislación no siempre garantizaría la atención de personas con condiciones preexistentes.
Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
A 22-year old man from Orange County, Calif., alleges in a lawsuit that his health insurer stopped paying for a crucial — and expensive — immunotherapy drug, leading him to become seriously ill. Treatments for patients with similar conditions are increasingly denied or interrupted, experts and patient advocates say.
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.